Bridget Keenan
Medical Oncology · San Francisco, CANPI 1497175798
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $11,936 of the $14,946 with a category attached, or 79.9%. F. Hoffmann-la Roche AG accounts for 81.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $12,216 and has fallen 98.5% since, to $184 in 2025.
Across 12 payments — averaging $1245.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$12K
- Regeneron$3K
- GSK$67
Across 144 payments — averaging $14,846 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1.2M
- Regeneron$340K
- Genentech, Inc.$236K
- AstraZeneca$202K
- Seagen Inc.$128K
- Astrazeneca UK Limited$41K
- plus $20K from 2 others
What the payments were for
- Consulting fees$2,31215%
- Travel & lodging$11,93680%
- Food & beverage$6314%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 4 | $12,216 |
| Regeneron | 7 | $2,663 |
| GSK | 1 | $67 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$117
How this compares
$14,946 in reported general payments places this provider in the 65th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in San Francisco
- Stephen SherwinSan Francisco$6.9M
- John ParkSan Francisco$558K
- Kevin KimSan Francisco$176K
- Aman ChauhanSan Francisco$99K
- Ana Velazquez MananaSan Francisco$90K
- Noam DrazinBeverly Hills$1.4M
- Farshid DayyaniOrange$1.2M
- April TeitelbaumSan Diego$1.1M
- Przemyslaw TwardowskiSanta Monica$995K
- Ann LowePalo Alto$923K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.